Market Runner: Does Teva Pharmaceutical Industries Ltd (ADR) Have Any Gas After Today’s Huge Decline?

Market Runner: Does Teva Pharmaceutical Industries Ltd (ADR) Have Any Gas After Today's Huge Decline?

The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is a huge mover today! About 2.22 million shares traded hands. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has declined 23.90% since March 10, 2016 and is downtrending. It has underperformed by 31.42% the S&P500.
The move comes after 6 months negative chart setup for the $46.02 billion company. It was reported on Oct, 13 by Barchart.com. We have $42.13 PT which if reached, will make NYSE:TEVA worth $2.30B less.

Analysts await Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) to report earnings on November, 3. They expect $1.30 EPS, down 3.70% or $0.05 from last year’s $1.35 per share. TEVA’s profit will be $1.35 billion for 8.53 P/E if the $1.30 EPS becomes a reality. After $1.25 actual EPS reported by Teva Pharmaceutical Industries Ltd (ADR) for the previous quarter, Wall Street now forecasts 4.00% EPS growth.

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Ratings Coverage

Out of 19 analysts covering Teva Pharma (NYSE:TEVA), 15 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 79% are positive. Teva Pharma has been the topic of 28 analyst reports since July 21, 2015 according to StockzIntelligence Inc. RBC Capital Markets maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Wednesday, July 29 with “Outperform” rating. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has “Buy” rating given on Monday, July 18 by HSBC. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has “Buy” rating given on Monday, July 27 by Standpoint Research. On Friday, September 2 the stock rating was upgraded by Oppenheimer to “Outperform”. Jefferies reinitiated the shares of TEVA in a report on Friday, October 30 with “Buy” rating. As per Thursday, July 14, the company rating was maintained by Oppenheimer. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has “Buy” rating given on Tuesday, July 28 by Citigroup. The firm earned “Neutral” rating on Friday, July 15 by Goldman Sachs. The company was initiated on Thursday, September 29 by OTR Global. The firm earned “Buy” rating on Friday, December 4 by Guggenheim.

According to Zacks Investment Research, “TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.”

TEVA Company Profile

Teva Pharmaceutical Industries Limited, incorporated on February 13, 1944, is a global pharmaceutical company. The Firm is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Firm operates through two divisions: Generic medicines and Specialty medicines. The Firm has a global portfolio of approximately 1,000 molecules.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment